Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib + FOLFOX in Advanced Solid Tumors and Colorectal Cancer
NCT00025142Phase 2Completed
- Sponsor
- Stanford University
- Start
- Jul 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib in solid tumor and colorectal cancer (CRC), sponsored by Stanford University. Primary endpoints: Maximum Tolerated Dose and Antitumor Response. Started Jul 2001; status: completed.
02
Drugs
03
Conditions
solid tumorcolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00025142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00025142.